Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | METAP2 | P50579 | 1/20 | 0.51 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | PDE4A | P27815 | 3/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.50 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.48 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.48 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.48 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.47 |
| ▸ | MLLT1 | Q03111 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10353459 | 0.87 | CYP1A2 (0.74) | CYP1A2LMNAPDE4APDE4BPDE4C | |
| SCHEMBL7298232 | 0.81 | CYP1A2 (0.65) | CYP1A2LMNAPDE4APDE4BPDE4C | |
| SCHEMBL3115615 | 0.80 | CYP1A2 (0.64) | CYP1A2LMNAPDE4APDE4BPDE4C | |
| SCHEMBL2829502 | 0.79 | CYP1A2 (0.62) | CYP1A2METAP2LMNAPDE4APDE4B | |
| SCHEMBL1301730 | 0.79 | CYP1A2 (0.62) | CYP1A2LMNAPDE4APDE4BPDE4C | |
| SCHEMBL10066830 | 0.79 | CYP1A2 (0.62) | CYP1A2METAP2LMNAPDE4APDE4B | |
| SCHEMBL4048920 | 0.79 | CYP1A2 (0.62) | CYP1A2LMNAPDE4APDE4BPDE4C | |
| SCHEMBL11628763 | 0.79 | KMT2A (0.64) | CYP1A2METAP2LMNAPDE4APDE4B | |
| SCHEMBL8890194 | 0.79 | CYP1A2 (0.50) | CYP1A2METAP2GPR119MLLT3MLLT1 | |
| SCHEMBL2152989 | 0.78 | LMNA (0.67) | CYP1A2LMNAPDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101678214-B | Aryl ether pyridazinone derivatives | MERCK PATENT GMBH | 2013-06-19 | — | — | CN | disclosed |
| US-8445489-B2 | Aryl ether pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-8445489-B2 | Aryl ether pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-8445489-B2 | Aryl ether pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-05-21 | — | — | US | disclosed |
| US-8173653-B2 | Pyridiazinone derivatives for the treatment of tumours | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8173653-B2 | Pyridiazinone derivatives for the treatment of tumours | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-05-08 | — | — | US | disclosed |
| EP-1960370-B1 | PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT | MERCK PATENT GMBH (DE) | 2011-10-05 | — | — | EP | disclosed |
| EP-2152370-B1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2011-07-06 | — | — | EP | disclosed |
| US-20100179149-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2010-07-15 | — | — | US | disclosed |
| US-20100179149-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2010-07-15 | — | — | US | disclosed |
| WO-2008145242-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-12-04 | — | — | WO | disclosed |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MERCK PATENT GESELLSCHAFT (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MERCK PATENT GESELLSCHAFT (DE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007065518-A1 | PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT | MERCK PATENT GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
| EP-0835865-B1 | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides | DOW AGROSCIENCES LLC (US) | 2003-03-12 | — | — | EP | disclosed |
| US-6121251-A | CONTROLLING PHYTOPATHOGENIC FUNGI, INSECTS | ROHM AND HAAS COMPANY (US) | 2000-09-19 | — | — | US | disclosed |
| EP-0835865-A1 | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides | ROHM AND HAAS COMPANY (US) | 1998-04-15 | — | — | EP | disclosed |
| US-5635494-A | CONTROLLING PHYTOPATHOGENIC FUNGI, INSECTS | ROHM AND HAAS COMPANY (US) | 1997-06-03 | — | — | US | disclosed |
| EP-0738716-A2 | Dihydropyridazinones and pyridazinones and their use as fungicides and insecticides | ROHM AND HAAS COMPANY (US) | 1996-10-23 | — | — | EP | disclosed |
| US-5135932-A | 2-HYDROXYPROPYLAMINO-ALKYL-BENZIMIDAZOLY-5-YL DERIVATIVES AND THEIR USE IN THE TREATMENT OF HEART DISEASE | DR. KARL THOMAE GMBH (DE) | 1992-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179149-A1 | ARYL ETHER PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | CYP1A2 388/4885METAP2 1351/4885HSD17B1 2677/4885 |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MET, RET, ERBB2 | CYP1A2 796/4885METAP2 513/4885HSD17B1 3023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.